Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

June 30, 2003

Conditions
Pulmonary Hypertension
Interventions
DRUG

BSF 208075

Trial Locations (21)

10032

New York Presbyterian Hospital, New York

30625

Hannover Medical School, Hanover

35392

University of Giessen, Giessen

37232

Vanderbilt University Medical Center, Nashville

40136

University of Bologna - Institute of Cardiology, Bologna

43210

Ohio State University, Columbus

44106

Case Western Reserve University, Cleveland

53215

Heart Care Associates, Milwaukee

55905

Mayo Clinic, Rochester

60612

Rush Presbyterian, Chicago

77030

Baylor College of Medicine, Houston

80262

University of Colorado Health Sciences Center, Denver

90089

University of Southern California, Los Angeles

90502

Los Angeles County Harbor-UCLA Medical Center, Torrance

92037

University of California San Diego Medical Center, San Diego

92141

Hopital Antoine Beclere, Clamart

94143

University of California - San Francisco, San Francisco

94305

Stanford University, Stanford

02115

Brigham and Women's Hospital, Boston

Unknown

St. Vincent's Hospital, Sydney

Erasmus University, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00046319 - Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter